These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25359359)

  • 1. Paving the critical path of drug development: the CDER perspective.
    Woodcock J
    Nat Rev Drug Discov; 2014 Nov; 13(11):783-4. PubMed ID: 25359359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.
    Parekh A; Buckman-Garner S; McCune S; ONeill R; Geanacopoulos M; Amur S; Clingman C; Barratt R; Rocca M; Hills I; Woodcock J
    Clin Pharmacol Ther; 2015 Mar; 97(3):221-33. PubMed ID: 25670629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One hundred years of drug regulation: where do we go from here?
    Woosley RL
    Annu Rev Pharmacol Toxicol; 2013; 53():255-73. PubMed ID: 23072378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How the Critical Path Initiative Addresses CDER's Regulatory Science Needs: Some Illustrative Examples.
    Geanacopoulos M; Barratt R
    Ther Innov Regul Sci; 2015 Jul; 49(4):466-472. PubMed ID: 30222436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FDA critical path initiative and its influence on new drug development.
    Woodcock J; Woosley R
    Annu Rev Med; 2008; 59():1-12. PubMed ID: 18186700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.
    Pariser AR; Slack DJ; Bauer LJ; Warner CA; Tracy LA
    Drug Discov Today; 2012 Aug; 17(15-16):898-904. PubMed ID: 22564486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of the Food and Drug Administration Electrocardiogram Warehouse: a paradigm for the critical pathway initiative.
    Cabell CH; Noto TC; Krucoff MW
    J Electrocardiol; 2005 Oct; 38(4 Suppl):175-9. PubMed ID: 16226096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways.
    Lynch HF; Bateman-House A
    J Law Med Ethics; 2020 Jun; 48(2):365-372. PubMed ID: 32631197
    [No Abstract]   [Full Text] [Related]  

  • 9. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Widening the path and window of opportunity for FDA approval of non-vitamin K oral anticoagulant specific antidotes and reversal agents.
    Patel S; Steen D
    J Thromb Thrombolysis; 2016 Feb; 41(2):285-92. PubMed ID: 26374107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA's 'Accelerated Approvals' Are Critical But Raise Thorny Issues.
    Miller HI
    Mo Med; 2019; 116(3):168-169. PubMed ID: 31527930
    [No Abstract]   [Full Text] [Related]  

  • 12. Caution urged over the FDA's new breakthrough designation.
    Jiang K
    Nat Med; 2013 Oct; 19(10):1196. PubMed ID: 24100969
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory watch: Characterizing the US FDA's approach to promoting transformative innovation.
    Downing NS; Krumholz HM; Ross JS; Shah ND
    Nat Rev Drug Discov; 2015 Nov; 14(11):740-1. PubMed ID: 26435528
    [No Abstract]   [Full Text] [Related]  

  • 14. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of worldwide clinical trials by gender: An FDA perspective.
    Ayuso E; Geller RJ; Wang J; Whyte J; Jenkins M
    Contemp Clin Trials; 2019 May; 80():16-21. PubMed ID: 30890465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paving the critical path: how can clinical pharmacology help achieve the vision?
    Lesko LJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):170-7. PubMed ID: 17259944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 18. Search for shortcuts on the critical path to market: US FDA perspectives from the diagnostic side.
    Gutman S; Hackett J
    Pharmacogenomics; 2006 Dec; 7(8):1223-7. PubMed ID: 17184209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What's next after 50 years of psychiatric drug development: an FDA perspective.
    Laughren TP
    J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.